Connect Biopharma Holdings Ltd
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $64.0K
- Net income
- -$55.5M
- Total assets
- $56.1M
- Market cap
- $136.6M
- Operating margin
- -90740.6%
- Net margin
- -86687.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $64.0K
- Operating expenses
- $58.1M
- Operating income
- -$58.1M
- Income tax
- $197.0K
- Net income
- -$55.5M
- EPS (basic)
- $-1.00
- EPS (diluted)
- $-1.00
Balance sheet
- Total assets
- $56.1M
- Current assets
- $50.9M
- Total liabilities
- $14.1M
- Current liabilities
- $13.6M
- Shareholders’ equity
- $42.0M
Cash flow
- Operating cash flow
- -$51.2M
- Investing cash flow
- $9.8M
- Financing cash flow
- $1.1M
- Net cash flow
- -$39.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $136.6M
- EPS (diluted)
- $-1.0
- Shares outstanding
- 65.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 3, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $55.5M in FY2025.
- Revenue declined 100% from FY2024 to FY2025.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Connect Biopharma Holdings Ltd.
Write a review
News about Connect Biopharma Holdings Ltd
News & sentiment via Polygon.io
